Metformin and Longevity: A Review of the Evidence

By Longevity Lab · Published: July 21, 2026

Based on peer-reviewed research — full source list at the end of this article. This is educational information, not medical advice.

Metformin is a cheap, decades-old prescription drug for Type 2 diabetes, and it is the most discussed candidate for a pill that slows aging. The honest state of the evidence: the benefit is well established in people with diabetes, the longevity signal comes from observational data, and no completed trial shows that metformin extends healthy life in people without diabetes. It is inexpensive, it has been in clinical use for decades, and its safety profile is decent. That is not the same as a reason for a healthy person to take it for longevity. Here is what is known, what is not, and why there is no case for rushing.

What metformin is and how it works

Metformin belongs to the biguanide class. Its ancestor is a compound from goat’s rue (French lilac), a plant used for centuries to lower blood sugar. Today metformin is the first-line drug for type 2 diabetes. It reduces glucose production by the liver and improves the sensitivity of tissues to insulin, with almost no risk of hypoglycemia. Your own insulin sensitivity can be gauged from ordinary blood work — glucose, triglycerides and HDL, together with BMI, are what feed the METS-IR: metabolic score for insulin resistance.

For the aging question, its secondary effects matter more. Metformin activates AMP-activated protein kinase (AMPK), the energy sensor of the cell. It gently alters mitochondrial function and the signaling pathways tied to aging, including mechanistic target of rapamycin (mTOR) indirectly, and it shifts the composition of the gut microbiome. Many of those mechanisms overlap with what happens during exercise and caloric restriction. That overlap is where the geroprotector hypothesis comes from.

Where the longevity interest came from

The trigger was observational data. In a large British analysis, people with type 2 diabetes taking metformin lived on average at least as long as, and by some estimates longer than, matched people without diabetes. That result is a paradox: the patients did as well as the healthy comparison group. It raised the idea that the benefit is not only glucose control but some additional effect of the drug itself.

Later meta-analyses of observational studies linked metformin use to lower all-cause mortality and a lower rate of several age-related diseases. Keep the caveat in view: these are associations, not proof. People who take metformin differ from people who do not on many variables, and comparisons like these mislead easily.

What human studies show

The honest picture from human data is restrained:

• in people with diabetes, the benefit of metformin is well established: it lowers blood glucose and cardiovascular risk;
• in healthy people, there are still no good long-term trials of life extension;
• there is one warning signal: in one study, metformin blunted part of the benefit of strength training and aerobic exercise in older adults, possibly by interfering with muscle adaptation;
• so for a physically active person, the drug could in theory work partly against the benefit of exercise.

That is why the caution around metformin runs so deep. The observations are appealing, and rigorous confirmation in healthy people does not exist. If what actually prompts the interest is your own glucose control, a screening estimate of the Risk of developing diabetes answers that question far more directly than a prescription would.

The TAME trial and what it is meant to show

To move the question from observation to evidence, researchers led by Nir Barzilai proposed the TAME trial (Targeting Aging with Metformin). The design is novel: instead of testing one disease, it targets the aging process itself, measuring whether several age-related diseases at once (heart disease, cancer, dementia) and death are delayed.

TAME matters for its precedent as much as for its result. It is meant to show regulators that aging can be treated as a target for therapy. For now the trial marks where the field is heading rather than a finished answer, and its results are what researchers are waiting for before drawing conclusions about metformin in healthy people.

Animal data

In animals the picture is less clean than the drug’s supporters would like. In some model organisms metformin extended lifespan, but in rigorous testing programs, in mice for example, the effect on lifespan was modest and dose-dependent, and doses that were too high did harm. That is another reason not to transfer expectations directly to humans.

Risks and side effects

Metformin is relatively safe, but it is not harmless:

• the most common effects are gastrointestinal (nausea, diarrhea, discomfort), especially in the first weeks;
• long-term use can lead to vitamin B12 deficiency, which is worth monitoring;
• a very rare but serious complication is lactic acidosis, and the risk rises with kidney disease;
• the drug is contraindicated in severe kidney failure and in a number of other conditions.

Metformin is a prescription drug. A physician, not a blogger and not the patient, should prescribe it, set the dose, and monitor safety.

Should you take metformin for longevity

The honest answer today: for healthy people, no, it is premature. There are intriguing observations and plausible mechanisms, and there is no proof that metformin extends healthy life in people who do not have diabetes. Add the possible conflict with the benefits of training and the real side effects, and self-prescribing “just in case” is not justified. Anyone who does take it long term on a doctor’s advice should also watch the nutrient side of the ledger, since B12 is the classic casualty among the Hidden deficiencies: B12, vitamin D, iron, magnesium, calcium that routine blood work can catch.

Investing in what is proven to work is far more reliable: movement, food, sleep, and not smoking (covered in detail in the guide how to slow aging). If TAME and the studies that follow confirm a benefit, the conversation changes. For now metformin is a promising candidate rather than a finished solution, and it is certainly not a replacement for the basics.

Frequently asked questions

Sources

Disclaimer. This article is for information only and does not replace medical advice. Talk to a qualified clinician before changing anything about your health.